Intravenous Stopcock - Market Insights, Competitive Landscape, and Market Forecast - 2030

Intravenous Stopcocks Market By Number Of Ports (Three-Way Stopcocks, Two-Way Stopcocks, And Multiple-Way Stopcocks), Application (Infusion Therapy And Pressure Monitoring), End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, Speciality Centers, And Others), And Geography (North America, Europe, Asia-Pacific, And Rest Of The World) are expected to grow at a steady CAGR forecast till 2030 owing to the increasing number of chronic diseases and increasing number of surgical procedures across the globe.

The intravenous stopcocks market is estimated to grow at a CAGR of 5.61% during the forecast period from 2024 to 2030. The market for intravenous stopcocks is significantly driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions, which necessitate regular and prolonged intravenous therapy. Additionally, the rising number of surgical procedures globally further boosts the demand, as intravenous stopcocks are essential for administering anesthesia, fluids, and medications during and after surgeries. These factors, coupled with the continuous improvement in healthcare infrastructure and increasing healthcare expenditure, contribute to the expanding adoption of the intravenous stopcocks market during the forecast period from 2024 to 2030.

Intravenous Stopcocks Market Dynamics:

According to the latest data provided by the GLOBOCAN (2024), in 2022 globally the total number of new cases of colorectal cancer, gallbladder cancer, prostate cancer, kidney cancer, brain, and central nervous system cancers was estimated at 4.27 million, with projections suggesting that cancer cases will increase to 5.24 million by the year 2030. This significant rise in cancer cases underscores the growing need for effective and reliable intravenous stopcocks for long-term needs which are essential for administering chemotherapy, pain management, and other supportive treatments thereby escalating the future market.

According, to the latest data provided by the World Health Organization (WHO) (2022), globally, healthcare-associated infections (HAIs) affect hundreds of millions annually, with 7 out of every 100 patients in high-income countries and 15 in low- and middle-income countries acquiring at least one HAI in acute care hospitals. In the EU/EEA, 8.9 million HAIs occur each year in acute and long-term care facilities. These alarming statistics highlight the critical need for infection prevention measures, promoting the demand for disposable intravenous stopcocks, which minimize the risk of cross-contamination. As healthcare systems prioritize reducing HAIs, the market for intravenous stopcocks is expected to grow significantly in the forecast period, driven by the need for safer, single-use medical devices.
Thus, according to the above mentioned factors the demand for intravenous stopcocks market, will increase during the forecast period.

However, the risk of contamination due to repeated use of the device and stringent regulatory approvals may hinder the market demand for intravenous stopcocks.

Intravenous Stopcocks Market Segment Analysis:

Intravenous Stopcocks Market by Number of Ports (Three-way Stopcocks, Two-way Stopcocks, and Multiple-way Stopcocks), Application (Infusion Therapy and Pressure Monitoring), End-Users (Hospitals & Clinics, Ambulatory Surgical Centers, Specialty Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the number of port segment of the intravenous stopcocks market, the three-way stopcocks category is estimated to have a significant revenue share in the intravenous stopcocks market in 2023. This can be attributed to the various advantages and applications provided by the three-way stopcocks. A three-way stopcock allows for three different connections, enabling the simultaneous administration of multiple fluids or medications. This is particularly useful in complex medical situations where multiple IV lines are needed. Additionally, the design of three-way stopcocks facilitates efficient fluid management and precise control over the flow rates, enhancing the overall safety and effectiveness of patient care. This increased functionality and the potential for streamlined operations make three-way stopcocks an essential tool in modern medical practice, offering a clear advantage over their two-way counterparts. For example, Smiths Medical - Medex™ Three-Way Stopcock allows the administration of multiple IV fluids or medications through a single access point.
The three-way design allows healthcare providers to quickly switch between different fluids or medications without disconnecting and reconnecting lines. This reduces the time needed for changing infusions and decreases the risk of contamination.

Therefore, the above-mentioned factors, can significantly boost the future market for intravenous stopcocks, meeting the increasing demand for safer and more efficient medical devices worldwide.

North America Is Expected To Dominate The Overall Intravenous Stopcocks Market:

North America is expected to account for the highest proportion of the global intravenous stopcocks market in 2023, out of all regions. The market for intravenous (IV) stopcocks in the United States is driven by several critical factors. The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions. Additionally, the high volume of surgical procedures, including both elective and emergency surgeries, growing emphasis on infection control, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the intravenous stopcocks market in North America.

According to data from GLOBOCAN (2024), in 2022, North America witnessed an estimated total of 553,000 collective new cases of colorectal cancer, gallbladder cancer, prostate cancer, kidney cancer, brain, and central nervous system cancers. By 2030, this number is projected to increase to 632,000 cases. As the cancer treatment often involves the administration of chemotherapy drugs, which are typically delivered intravenously. The use of intravenous stopcocks in these procedures allows for precise control and management of the medication flow, making them essential in oncology departments thereby boosting the market in North America.
According to the recent data provided by the U.S Department of Health and Human Service (2021), about 1 in 31 inpatients develop infections during their stay at hospital in the United States. Thus, healthcare-associated infections, further fuels the adoption of disposable stopcocks which helps to minimize contamination and will drive the market demand in the United States.

According to the recent data provided by Centre for Disease Control and Prevention (CDC), in 2021, in the U.S., 38.4 million people of all ages, representing 11.6% of the population, have diabetes, with the prevalence among adults increasing with age, reaching 29.2% in those aged 65 years or older. Thus, the high prevalence of diabetes in the U.S. will boost the market for intravenous stopcocks due to the increased need for frequent and reliable IV access for insulin administration, management of diabetic complications, and other related therapies.
Therefore, the aforementioned factors collectively contribute to the positive growth trajectory of the intravenous stopcock market in the United States, highlighting the increasing demand and critical role these devices play in modern healthcare settings.

Intravenous Stopcocks Market Key Players:

Some of the key market players operating in the intravenous stopcocks include B. Braun Melsungen AG, 3M, Terumo Corporation, Abbott., Teleflex Incorporated., Henry Schein, Inc., Miths Medical, ICU Medical, Inc., Qosina., Guerbet, Baxter, Ascor S.A., Moog Inc., AngioDynamics., Fresenius SE & Co. KGaA, Animas LLC, International WIN, LTD., The Metrix Company, Dispowell Surgicals, Vygon, and others

Recent Developmental Activities In The Intravenous Stopcocks Market:

• In September 2023, Qosina, a worldwide supplier of single-use medical and pharmaceutical components, introduced the RondelO™ stopcock manifold.
• In May 2020, Guerbet, a leader in medical imaging, announced that Vectorio® has been registered in Canada. Vectorio® is a set of medical tools resistant to Lipiodol® and is used to image hepatocellular carcinoma (HCC). It includes patented syringes, stopcocks, and sampling devices.

Key Takeaways From The Intravenous Stopcocks Market Report Study

• Market size analysis for current intravenous stopcocks market size (2023), and market forecast for 6 years (2024 to 2030)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global intravenous stopcocks market.
• Various opportunities available for the other competitors in the intravenous stopcocks market space.
• What are the top-performing segments in 2023? How these segments will perform in 2030?
• Which are the top-performing regions and countries in the current intravenous stopcocks market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for intravenous stopcocks market growth in the coming future?

Target Audience Who Can Be Benefited From This Intravenous Stopcocks Market Report Study

• Intravenous stopcocks product providers
• Research organizations and consulting companies
• Intravenous stopcocks organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in intravenous stopcocks
• Various end-users who want to know more about the intravenous stopcocks market and the latest technological developments in the intravenous stopcocks market.

Frequently Asked Questions For The Intravenous Stopcocks Market:

1. What are intravenous stopcocks?

Intravenous (IV) stopcocks are medical devices used in healthcare settings to control the flow of fluids or medications into and out of IV lines. They are designed with multiple ports that allow for the connection of various IV lines or devices.

2. What is the market for intravenous stopcocks?

The intravenous stopcocks market is estimated to grow at a CAGR of 5.61% during the forecast period from 2024 to 2030.

3. What are the drivers for the global intravenous stopcocks market?

The market for intravenous stopcocks is significantly driven by the the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions, which necessitate regular and prolonged intravenous therapy. Additionally, the rising number of surgical procedures globally further boosts the demand, as intravenous stopcocks are essential for administering anesthesia, fluids, and medications during and after surgeries. These factors, coupled with the continuous improvement in healthcare infrastructure and increasing healthcare expenditure, contribute to the expanding adoption of the intravenous stopcocks market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the global intravenous stopcocks market?

Some of the key market players operating in the Intravenous stopcocks included B. Braun Melsungen AG, 3M, Terumo Corporation, Abbott., Teleflex Incorporated., Henry Schein, Inc., Miths Medical, ICU Medical, Inc., Qosina., Guerbet, Baxter, Ascor S.A., Moog Inc., AngioDynamics., Fresenius SE & Co. KGaA, Animas LLC, International WIN, LTD., The Metrix Company, Dispowell Surgicals, Vygon, and others.

5. Which region has the highest share in the global intravenous stopcocks market?

North America is expected to account for the highest proportion of the global intravenous stopcocks market in 2023, out of all regions. The increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular conditions. Additionally, the high volume of surgical procedures, including both elective and emergency surgeries, growing emphasis on infection control, and a highly viable market in terms of product development, and launches are some of the key factors driving the growth of the intravenous stopcocks market in North America.


This product will be delivered within 2 business days.